Subscribe
News

Omicron-specific boosters fail to show benefit over original shots, study finds

By Abigail Adcox
Published
Add Washington Examiner on Google
Omicron-specific boosters fail to show benefit over original shots, study finds

The newest omicron COVID-19 booster shots from Moderna and Pfizer-BioNTech do not increase neutralizing antibodies, proteins produced in the body that help prevent infection, against omicron subvariants BA.4 and BA.5 compared to four of the original COVID-19 shots, according to a small-scale independent study.

Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.

Tag:

COVID-19 Pfizer research Vaccines